IPHYF (Innate Pharma) LT-Debt-to-Total-Asset: 0.22 (As of Dec. 2025)

What is Innate Pharma LT-Debt-to-Total-Asset?

Innate Pharma IPHYF 29 LT-Debt-to-Total-Asset is 0.22 as of Dec. 2025. GuruFocus rates IPHYF with a GF Score™ of 29/100 and a GF Value™ of $0.14 (Significantly Overvalued). The stock has 7 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Innate Pharma's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.22.

Innate Pharma's long-term debt to total assets ratio increased from Dec. 2024 (0.20) to Dec. 2025 (0.22). It may suggest that Innate Pharma is progressively becoming more dependent on debt to grow their business.

Innate Pharma (OTCPK:IPHYF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Innate Pharma LT-Debt-to-Total-Asset Related Terms

Innate Pharma LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Innate Pharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innate Pharma LT-Debt-to-Total-Asset Chart

Innate Pharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.05

0.20

0.18

0.20

0.22

Innate Pharma Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.18	0.18	0.20	0.20	0.22

29GF Score

Innate Pharma SA IPHYF

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Innate Pharma LT-Debt-to-Total-Asset Calculation

Innate Pharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	16.125	/	73.441
	=	0.22

Innate Pharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )	/	Total Assets (Q: Dec. 2025 )
	=	16.125	/	73.441
	=	0.22

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.22 mean?

Innate Pharma (IPHYF) has a LT-Debt-to-Total-Asset of 0.22 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Innate Pharma and its competitors.

Is Innate Pharma's LT-Debt-to-Total-Asset too high?

Innate Pharma's current LT-Debt-to-Total-Asset is 0.22. Overall, Innate Pharma has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Innate Pharma's LT-Debt-to-Total-Asset compare to VRTX and REGN?

Innate Pharma's LT-Debt-to-Total-Asset of 0.22 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Innate Pharma and its competitors. Innate Pharma's current LT-Debt-to-Total-Asset is 0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Innate Pharma stock overvalued right now?

Based on GuruFocus' analysis, Innate Pharma (IPHYF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.14, compared to a current price of $1.65 — trading 1078.6% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.22. Innate Pharma's overall GF Score™ is 29/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Innate Pharma (IPHYF), the current LT-Debt-to-Total-Asset is 0.22 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Innate Pharma (IPHYF) Overvalued in 2026?

Based on GuruFocus' analysis, Innate Pharma stock appears to be overvalued. The current stock price of $1.65 is trading 1078.6% above its estimated GF Value™ of $0.14. GuruFocus considers Innate Pharma to be Significantly Overvalued.

Key valuation signals for IPHYF:

LT-Debt-to-Total-Asset: 0.22
GF Value™: $0.14 vs. price of $1.65 (1078.6% above fair value)
GF Score™: 29/100 with 7 warning signs

No single metric tells the full story. See the IPHYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Innate Pharma Business Description

Industry Healthcare Biotechnology

Comparable Companies XPAR:ALSEN XPAR:ALVIO XPAR:TNG XPAR:ABNX XPAR:ADOC XPAR:OSE XPAR:ALGAE XPAR:ALCLS XPAR:MAAT XPAR:ALTHX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges IPHA:USA 0EVI:UK IPH:France IDD:Germany

Address 117, Avenue de Luminy, Marseille, FRA, 13009

Website https://www.innate-pharma.com

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

29GF Score

Get the complete analysis for IPHYF

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.65

Price

$0.14

GF Value

View IPHYF Analysis

See LT-Debt-to-Total-Asset data for all stocks →